Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pivotal Phase III Trial to Investigate the Efficacy and Safety of an Orodispersible Tablet Vardenafil Versus Placebo in the Treatment of Men With Erectile Dysfunction (ED) - a Fixed-Dose, Double-Blind, Randomized Multi-Center Trial - POTENT I.

Trial Profile

Pivotal Phase III Trial to Investigate the Efficacy and Safety of an Orodispersible Tablet Vardenafil Versus Placebo in the Treatment of Men With Erectile Dysfunction (ED) - a Fixed-Dose, Double-Blind, Randomized Multi-Center Trial - POTENT I.

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jan 2015

At a glance

  • Drugs Vardenafil (Primary)
  • Indications Erectile dysfunction
  • Focus Registrational; Therapeutic Use
  • Acronyms POTENT-1
  • Sponsors Bayer
  • Most Recent Events

    • 13 Feb 2013 Planned number of patients changed from 350 to 362 as reported by German Clinical Trials Register.
    • 13 Feb 2013 New source identified and integrated (German Clinical Trials Register; DRKS00004143).
    • 06 Sep 2010 Secondary endpoint 'Sexual Encounter Profile' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top